This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Cerevel Therapeutics Class Action Lawsuit
Business class action lawsuit

Cerevel Therapeutics Class Action Lawsuit

Analysis based on 10 articles · First reported Apr 17, 2025 · Last updated May 01, 2025

Sentiment
-20
Attention
3
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Coeptis Therapeutics Holdings and its controlling shareholder Bain Capital could lead to significant financial penalties and reputational damage for both entities. The allegations of undisclosed information and artificial stock price deflation may erode investor confidence in Coeptis Therapeutics Holdings and potentially impact future M&A activities in the pharmaceutical sector.

Pharmaceuticals Legal Services
Event Summary

The Gross Law Firm has issued a notice to shareholders of Coeptis Therapeutics Holdings Holdings, Inc. regarding a class action lawsuit. The lawsuit alleges that Coeptis Therapeutics Holdings' October 16, 2023 secondary stock offering and other public statements omitted material facts about AbbVie Inc.'s interest in acquiring Coeptis Therapeutics Holdings at a price significantly higher than the offering price, thereby artificially deflating Coeptis Therapeutics Holdings' stock. Furthermore, Coeptis Therapeutics Holdings' controlling shareholder, Bain Capital, is accused of acquiring Coeptis Therapeutics Holdings shares from the October Offering at an artificially depressed price while allegedly possessing material nonpublic information about AbbVie Inc.'s interest, leading to a windfall for Bain Capital. The lawsuit also claims that Coeptis Therapeutics Holdings' January 18, 2024 Proxy statement misled investors regarding the true nature and timing of AbbVie Inc.'s interest. The deadline for shareholders to seek lead plaintiff appointment is June 3, 2025.

Key Actions
90 Bain Capital acquired shares Coeptis Therapeutics Holdings
85 Coeptis Therapeutics Holdings omitted material facts
80 AbbVie agreed to acquire Coeptis Therapeutics Holdings
Entities Involved
stock
Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings is the target of a class action lawsuit alleging that its secondary stock offering and proxy statement omitted material facts regarding AbbVie Inc.'s interest in acquiring it, leading to an artificially deflated stock price.
Importance 90.0 Sentiment -30.0
priv
Bain Capital
Bain Capital, as Coeptis Therapeutics Holdings' controlling shareholder, is accused of acquiring Coeptis Therapeutics Holdings shares at an artificially depressed price while allegedly possessing material nonpublic information about AbbVie Inc.'s acquisition interest, resulting in a significant windfall.
Importance 80.0 Sentiment -40.0
stock
AbbVie
AbbVie Inc. is implicated in the lawsuit for its alleged undisclosed interest in acquiring Coeptis Therapeutics Holdings at a higher price than the secondary offering, which supposedly led to an artificially deflated stock price for Coeptis Therapeutics Holdings.
Importance 70.0 Sentiment -10.0
Relationships
Coeptis Therapeutics Holdings investee ↔ Bain Capital Coeptis Therapeutics Holdings is an investee of Bain Capital, which orchestrated a secondary offering to acquire additio
Coeptis Therapeutics Holdings target ↔ AbbVie Cerevel Therapeutics Holdings agreed to be acquired by pharmaceutical giant AbbVie for $45 per share in December 2023.
Bain Capital unrelated ↔ AbbVie Bain Capital does not have a direct structural or commercial relationship with AbbVie.
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.